What is RoosterBio?
Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio operates as a specialized platform technology company. Its core mission is to accelerate the development of a sustainable regenerative medicine industry by providing standardized, high-quality cell manufacturing solutions. By streamlining the supply chain for cell-based therapies, the company effectively lowers the barrier to entry for developers, ensuring that life-saving treatments can reach patients with greater efficiency and reliability. The company's market position is defined by its commitment to industrializing biological processes, effectively bridging the gap between academic discovery and clinical application.
How much funding has RoosterBio raised?
RoosterBio has raised a total of $35.9M across 6 funding rounds:
Private Equity
$5.2M
Debt
$1.3M
Series A
$6M
Series B
$21.5M
Debt
$1M
Debt
$990K
Private Equity (2016): $5.2M, investors not publicly disclosed
Debt (2017): $1.3M, investors not publicly disclosed
Series A (2017): $6M, investors not publicly disclosed
Series B (2019): $21.5M featuring Bioeconomy Capital, Dynamk Capital, and Vanedge Capital
Debt (2020): $1M backed by PPP
Debt (2021): $990K with participation from PPP
Key Investors in RoosterBio
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy, focusing on biological engineering and production technologies.
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies.
Vanedge Capital
Vanedge Capital is an early-stage venture capital fund based in Vancouver, Canada, focusing on empowering visionary technologists in the Hard Tech and AI & Analytics sectors to scale foundational technology companies.
What's next for RoosterBio?
With the support of its recent capital injection, RoosterBio is well-positioned to scale its manufacturing infrastructure and expand its product portfolio. The strategic focus will likely center on enhancing the scalability of its cell-based platforms and deepening its integration within the global bio-manufacturing supply chain. As the regenerative medicine market matures, RoosterBio's ability to provide consistent, high-quality inputs will be essential for partners navigating the complexities of clinical trials and regulatory approval. The company remains a key candidate for further institutional financing as it continues to define the standards for the next generation of therapeutic production.
See full RoosterBio company page
